Press Releases

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Press Releases

News Releases

Date Title and Summary
Toggle Summary KemPharm, Inc. Receives Additional Notice of Allowance for Novel Prodrugs of Hydrocodone
North Liberty, IA – August 7, 2013 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for
Toggle Summary KemPharm, Inc. Appoints Gordon K. "Rusty" Johnson as Chief Operating Officer and Chief Financial Officer
30-Year Investment Banking Veteran Joins KemPharm to Strengthen its Business & Financial Operations North Liberty, IA – July 15, 2013 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today the
Toggle Summary KemPharm, Inc. Receives Patent from the USPTO for Novel Pain Drug Candidate, KP201
North Liberty, IA – June 11, 2013 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No.
Toggle Summary KemPharm's KP201 Featured at the International Conference on Opioids
Poster Presentation to Highlight KP201's Unique Abuse-Deterrent Properties and Its Potential to Prevent or Reduce Opioid-Induced Constipation North Liberty, IA – June 4, 2013 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer
Toggle Summary KemPharm, Inc. Receives Notice of Allowance for Novel Pain Drug Candidate, KP201
North Liberty, IA – April 3, 2013 – KemPharm, Inc, a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its
Toggle Summary KemPharm Supports Recent FDA Recommendations for Hydrocodone-Containing Compounds and Abuse-Deterrent Opioids
"Opioid-based therapeutics manage pain very well, but safe-guards and technological enhancements are needed to mitigate a clear abuse risk," Travis C. Mickle, Ph.D. North Liberty, IA – February 14, 2013 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and
Toggle Summary KemPharm, Inc Receives USAN Approval for Nonproprietary Name of Novel Pain Drug Candidate, KP201
Benzhydrocodone's Unique Physicochemical and Pharmacological Attributes Offer Potential to Reduce Abuse and Opioid-Induced Constipation North Liberty, IA – January 7, 2013 – KemPharm, Inc, a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to
Toggle Summary KemPharm, Inc. Receives Positive Feedback from FDA on KP201 Clinical Plan
Toggle Summary KemPharm, Inc. Presents Key Findings for Novel Hydromorphone Prodrug at 2012 International Conference on Opioids (link to poster presentation)
Toggle Summary KemPharm Inc. Focuses on Advanced Pain Management Franchise